Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model

BACKGROUND: Ferric citrate (FC) is a phosphate binder in development for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD). In clinical trials, FC improved patient serum phosphorus levels and increased serum ferritin and percent transferrin saturation. Because nephro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutell, Richard, Rubin, Jaime L, Bond, T Christopher, Mayne, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647605/
https://www.ncbi.nlm.nih.gov/pubmed/23662073
http://dx.doi.org/10.2147/IJNRD.S40729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647605/
https://www.ncbi.nlm.nih.gov/pubmed/23662073
http://dx.doi.org/10.2147/IJNRD.S40729

Ejemplares similares